Nanochon raised $4 million in its series seed prime fundraising round, led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from cultivate(MD), Alumni Venture Group and Mountain State Capital, among others.
The company has developed the Chondrograft device that allows for immediate weight-bearing and motion in the treatment of lost or damaged cartilage. Chondrograft requires only minimally invasive surgery to regrow damaged cartilage and bone to delay the need for full knee replacement.
Nanochon intends to use the funds to initiate its Phase I first in human clinical trials in the U.S. in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team.
“We’re thrilled to close our funding round and begin our clinical program,” says Ben Holmes, CEO and co-founder. “Securing this funding is one step closer towards achieving Nanochon’s goals of eliminating the need for knee replacements, and greatly shifting the paradigm of arthritic joint care…We’ve had fantastic success in our animal studies and we’re very optimistic about future implications in human knees and other joints.”
Nanochon raised $4 million in its series seed prime fundraising round, led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from cultivate(MD), Alumni Venture Group and Mountain State Capital, among others.
The company has developed the Chondrograft device that allows for immediate weight-bearing and...
Nanochon raised $4 million in its series seed prime fundraising round, led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from cultivate(MD), Alumni Venture Group and Mountain State Capital, among others.
The company has developed the Chondrograft device that allows for immediate weight-bearing and motion in the treatment of lost or damaged cartilage. Chondrograft requires only minimally invasive surgery to regrow damaged cartilage and bone to delay the need for full knee replacement.
Nanochon intends to use the funds to initiate its Phase I first in human clinical trials in the U.S. in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team.
“We’re thrilled to close our funding round and begin our clinical program,” says Ben Holmes, CEO and co-founder. “Securing this funding is one step closer towards achieving Nanochon’s goals of eliminating the need for knee replacements, and greatly shifting the paradigm of arthritic joint care…We’ve had fantastic success in our animal studies and we’re very optimistic about future implications in human knees and other joints.”
Copy to clipboard 
